Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1923]

PARP inhibitor olaparib added to bevacizumab benefits women with ovarian cancer...

Prof Isabelle Ray-Coquard - The Université Claude Bernard Lyon, Lyon, France

PARP inhibitor olaparib added to bevacizumab benefits women with ovarian cancer with and without a BRCA mutation ( Prof Isabelle Ray-Coquard - The Université Claude Bernard Lyon, Lyon, France )

Nivolumab plus ipilimumab combination offers chemotherapy-free option for...

Prof Solange Peters - Centre Hospitalier Universitaire Vaudois, Lausanne...

Nivolumab plus ipilimumab combination offers chemotherapy-free option for advanced NSCLC ( Prof Solange Peters - Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland )

Comment: PARP inhibitor olaparib plus bevacizumab in women with ovarian cancer

Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK

Comment: PARP inhibitor olaparib plus bevacizumab in women with ovarian cancer ( Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK )

More ovarian cancer patients benefit from maintenance combined targeted therapy

Prof Isabelle Ray-Coquard - The Université Claude Bernard Lyon, Lyon, France

More ovarian cancer patients benefit from maintenance combined targeted therapy ( Prof Isabelle Ray-Coquard - The Université Claude Bernard Lyon, Lyon, France )

Comment: Immunotherapy combination for advanced NSCLC

Dr Marina Garassino - National Tumour Institute, Milan, Italy

Comment: Immunotherapy combination for advanced NSCLC ( Dr Marina Garassino - National Tumour Institute, Milan, Italy )

D-VTd in transplant-eligible newly diagnosed MM: Subgroup analysis of high-risk...

Prof Pieter Sonneveld - Erasmus MC Cancer Institute, Rotterdam, Netherlands

D-VTd in transplant-eligible newly diagnosed MM: Subgroup analysis of high-risk patients in CASSIOPEIA ( Prof Pieter Sonneveld - Erasmus MC Cancer Institute, Rotterdam, Netherlands )

A phase 1b study of once-weekly KRd in patients with newly diagnosed multiple...

Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA

A phase 1b study of once-weekly KRd in patients with newly diagnosed multiple myeloma ( Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA )

Comparative effectiveness of lenalidomide, bortezomib, and their combinations...

Dr Peter Barth - Rhode Island Hospital, Philadelphia, USA

Comparative effectiveness of lenalidomide, bortezomib, and their combinations for elderly myeloma patients ( Dr Peter Barth - Rhode Island Hospital, Philadelphia, USA )

Twice-weekly vs once-weekly Krd in early relapsed refractory multiple myeloma

Prof Xavier Leleu - CHU la Miletrie, Poitiers, France

$Twice-weekly vs once-weekly Krd in early relapsed refractory multiple myeloma ( Prof Xavier Leleu - CHU la Miletrie, Poitiers, France )$

Maintenance with weekly carfilzomib in elderly newly diagnosed multiple myeloma

Prof Xavier Leleu - CHU la Miletrie, Poitiers, France

Maintenance with weekly carfilzomib in elderly newly diagnosed multiple myeloma ( Prof Xavier Leleu - CHU la Miletrie, Poitiers, France )

Real-world use of carfilzomib therapy among patients with existing...

Prof Xavier Leleu - CHU la Miletrie, Poitiers, France

Real-world use of carfilzomib therapy among patients with existing cardiovascular medical history ( Prof Xavier Leleu - CHU la Miletrie, Poitiers, France )

Improved outcomes from quadruplet KCRD induction in newly diagnosed myeloma...

Dr Charlotte Pawlyn - Royal Marsden Hospital, London, UK

Improved outcomes from quadruplet KCRD induction in newly diagnosed myeloma patients ( Dr Charlotte Pawlyn - Royal Marsden Hospital, London, UK )

More from ecancer